Document is current
Any future updates will be listed below
-
Authors
Kong, Tim https://orcid.org/0000-0002-3240-8989
Laranjeira, Angelo B. A.
Letson, Christopher T.
Yu, LaYow https://orcid.org/0009-0004-7849-0844
Lin, Shuyang
Fowles, Jared S.
Fisher, Daniel A. C.
Ng, Sherwin
Yang, Wei
He, Fan
Youn, Minyoung https://orcid.org/0000-0002-8112-2346
Mark, Kailen
Jose, Ana San
Liu, Jingxian
Kim, Alexander B.
Cox, Maggie J.
Fulbright, Mary C.
Jayanthan, Aarthi
Los, Gerrit
Rentschler, Stacey L. https://orcid.org/0000-0002-1744-1238
Ding, Li https://orcid.org/0000-0003-1517-2975
Sakamoto, Kathleen M.
Dunn, Sandra E.
Challen, Grant A. https://orcid.org/0000-0003-4669-8814
Oh, Stephen T. https://orcid.org/0000-0002-8564-5400
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HL134952)
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 19 December 2024
First Online: 16 January 2025
Competing interests
: S.T.O. has served as a consultant for Kartos Therapeutics, CTI BioPharma, Celgene/Bristol Myers Squibb, Disc Medicine, Protagonist, Blueprint Medicines, Cogent, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, and Incyte. A.J., G.L., and S.E.D. are employees of Phoenix Molecular Designs. S.E.D. holds patents on utilizing RSK inhibitors for the treatment of cancer. G.A.C. has received funding for consulting and/or sponsored research from Incyte, Ajax Therapeutics, and Renegade Therapeutics. All other authors disclose no competing interests.
